Furthermore, administration of VEGF‐C156S prevented and reversed the development of hypertrophic remodeling in mice subjected to overload, suggesting that selective stimulation of cardiac lymphangiogenesis may be a new therapeutic option for the treatment of HF. This evidence concerns the gene VEGFA and hydrops fetalis.